Introduction {#Sec1}
============

The prevalence of diabetes continues to rise each year. In 2011, it was estimated that approximately 366 million people---7% of the world's population---had diabetes, with approximately 80% of these people living in developing countries \[[@CR1]\]. The expectation is that these numbers will increase to 552 million adults (8.3% of the world's population) by 2030 \[[@CR1]\]. Complications due to diabetes are also a growing public health problem. One of the most common complications of diabetes is diabetic foot ulcers (DFUs). DFUs are complex chronic wounds that have a major long-term impact on the morbidity, mortality and quality of patients' lives \[[@CR2], [@CR3]\]. Individuals who develop DFUs are at greater risk of premature death, myocardial infarction and fatal stroke than those without a history of this complication \[[@CR4]\]. Approximately 25% of people with diabetes will develop a lower extremity ulcer over time \[[@CR5], [@CR6]\]. The treatment of these wounds remains challenging as they are often slow to heal and frequently reoccur. The poor prognosis of DFUs is attributed to those conditions often associated with diabetes, such as peripheral vascular diseases, neuropathy and poor blood glucose control. The delayed healing of ulcers increases the risk for severe wound infection and amputation \[[@CR7], [@CR8]\]; approximately half of all people undergoing non-traumatic amputations are diagnosed with diabetes \[[@CR9]\], with studies showing that up to 88% of all diabetes-related amputations are preceded by a foot ulcer \[[@CR10], [@CR11]\]. Amputation can in turn increase morbidity and healthcare costs while at the same time reduce an individual's productivity and quality of life. Moreover, the mortality following amputation increases with level of amputation \[[@CR12]\]. A 5-year mortality rate is very high among patients with any amputation (major and minor combined), ranging from 53 to 100%, and in patients with major amputation, it ranges from 52 to 80% \[[@CR13]\]. Mortality following amputation is comparable to many types of cancer \[[@CR10]\]. Therefore, any treatment that can reduce amputation rates is more than welcome. The main goal of treating DFUs is to promote a rapid and complete healing in order to reduce the risk of infection, amputation and other form of related complications.

Moist dressings, debridement, wound offloading and infection control are standard therapy or standard of care (SOC) in the management of DFUs. Standard therapy is commonly used in many clinic centers across the world. The Wound Healing Society guidelines recommend consideration of advanced wound therapies if the diabetic ulcer does not decrease in size by 40% or more after 4 weeks of standard therapy \[[@CR14]\]. However, the guidelines of the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine recommend adjunctive wound therapy if DFUs fail to improve (reduction of \>50% wound area) after a minimum of 4 weeks of standard wound therapy \[[@CR15]\].

Processed human amnion/chorion membrane (cryopreserved, dehydrated or acellular) is considered to be an adjunctive wound therapy. Several studies have recently shown its effectiveness in diabetic wound healing \[[@CR16], [@CR17]\]. It promotes wound closure, resulting in a more consistent and faster healing of chronic DFUs when compared with standard therapy alone \[[@CR18]\]. In fact, many studies have shown human amniotic membrane has properties that enhance healing. The PURION^®^ processed dehydrated human amnion/chorion membrane (dHACM) retains biologically active growth factors and regulatory factors that are in part responsible for its clinical effectiveness in wound healing \[[@CR19]\]. dHACM can stimulate diabetic adipose-derived stem cells (ADSCs) to migrate, proliferate and alter cytokine expression, suggesting that ADSCs may respond to dHACM to accelerate diabetic wound healing \[[@CR20]\]. Cell-seeded acellular amniotic membrane has the potential to deliver autologous or allogeneic cells to treat a variety of conditions, including DFUs, corneal defect and severe skin burns \[[@CR21]\]. Cryopreserved human amniotic membrane retains all of its native human amniotic membrane components, including viable endogenous cells that can enhance angiogenic activity in chronic wounds \[[@CR22]\]. Amnion products are now available and can be found in different forms according to their components or processing methods \[[@CR23]\].

To further evaluate the efficacy and time sensitivity of human amnion/chorion membrane (HACM) allografts in patients with chronic DFUs, we performed a systematic review and meta-analysis to compare HACM + SOC with SOC alone (HACM + SOC vs. SOC alone), since there has never been any systematic review and meta-analysis of this topic.

Methods {#Sec2}
=======

Study Selection and Data Extraction {#Sec3}
-----------------------------------

The PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched for relevant papers up to and including 10 April 2017. To identify all relevant studies, we used the search terms "diabetic foot ulcers" OR "diabetic foot" AND "amniotic membrane" OR "amnion" OR "bioimplant dressing" OR "Grafix" OR "EpiFix" AND "standard therapy "or "standard of care."

The eligibility criteria were: (1) prospective randomized control trials (RCTs); (2) studies comparing human amniotic membrane + standard therapy versus standard therapy in patients with DFUs; (3) studies in which an assessment of wound healing rates was conducted at least within a period of no less than 4 weeks and no more than 12 weeks; (4) studies published in English; (5) studies with complete outcome. Studies were excluded when they did not fulfill these inclusion criteria.

A flowchart of the study selection is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flowchart of study selection

To be able to focus on the efficacy and time sensitivity of HACM + SOC treatment, the outcomes of the seven studies included in our analysis were subdivided into three groups: (1) assessment at 4 weeks \[[@CR24], [@CR25]\]; (2) assessment at 6 weeks \[[@CR24]--[@CR28]\]; (3) assessment at 12 weeks \[[@CR26], [@CR29], [@CR30]\].

The three groups of assessment time points with respect to incomplete healing are shown in a forest plot in Fig. [2](#Fig2){ref-type="fig"}. In each group, we compared unhealed ulcers using two interventions (HACM + SOC and SOC alone).Fig. 2Forest plot of incomplete healing at the different assessment time points comparing combined HACM + SOC treatment versus SOC alone. HACM Human amnion/chorion membrane, SOC standard of care/standard therapy, CI confidence interval

Study Quality and Risk of Bias Assessment {#Sec4}
-----------------------------------------

All of the authors worked independently to search for and assess studies for their methodological quality. The Cochrane Collaboration's tool for assessing the risk of bias was used. This tool includes seven entries: random sequence generation, allocation concealment, blinding of participants, blinding of personnel, blinding of outcome assessor, incomplete outcome data and selective reporting. If one study had more than two "high-risk" entries, it was considered to be of low quality; otherwise, it was considered to be of high quality \[[@CR31]\]. Any disagreement in the assessment of studies was resolved by consensus and, if necessary, Qing Feng Cheng and Qi Fu Li were consulted.

Statistical Analysis {#Sec5}
--------------------

Odds ratios (ORs) with 95% of confidence interval (CIs) were calculated to assess the effect of dichotomous data. *I* ^2^ and *P* values were calculated to assess the heterogeneity among studies (*I* ^2^ \> 50% and/or *P* \< 0.1 were considered to be statistically significant). The ORs were pooled using only a random effects model to calculate a more conservative result. When ORs were \<1, the intervention was associated with lower risk on outcome; when ORs were \>1, the intervention was more associated with higher risk on outcome. Subgroup analyses were performed according to the time of wound healing assessment. The subgroup differences were also tested. Sensitivity analyses were performed on the high-quality studies. *P* \< 0.05 was considered to indicate a statistically significant difference in outcome between HACM + SOC and SOC alone. Review Manager version 5.3 software was employed for the statistical analyses.

Compliance with Ethics Guidelines {#Sec6}
---------------------------------

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec7}
=======

A total of 352 published studies were retrieved from the four databases, among which 47 were potentially relevant. Further study of these 47 potentially relevant papers revealed that 40 were overlapping studies and subsequently excluded from the analysis. Seven studies were ultimately were included in the meta-analysis \[[@CR24]--[@CR30]\] (Fig. [1](#Fig1){ref-type="fig"}), of which six were conducted in USA and one was conducted in Iran. The studies and the properties of the commercial amniotic membrane products are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1Details on the seven studies included in the meta-analysisReferencesStudy design, region and yearPeriod of enrollment and target populationTreatment groupsDefinition of ulcers*n*Zelen et al. \[[@CR24]\]Single-center nonblinded RCT in southwest Virginia (USA); 2013Patients with DFUsdHACM (EpiFix; MiMedx, Marietta, GA) + SOC vs. SOCUlcer size \>1 and \<25 cm^2^\
Ulcer duration of \>4 weeks\
No clinical sign of infection25Mohajeri-Tehrani et al. \[[@CR27]\]RCT in Tehran, Iran; 2016November 2010 till March 2012; patients with DFUsAHAM + SOC vs. SOCUlcer size \>2 cm^2^\
Control group (IW = 16)\
Intervention group (IW = 11)57Lavery et al. \[[@CR30]\]Multicenter, single- blinded RCT, in USA; 2016May 2012 to April 2013; patients with DFUsCryopreserved human amniotic membrane (Grafix; Osiris Therapeutics, Inc., Columbus, MD) + SOC vs. SOCUlcer size \>1 and \<15 cm^2^\
Ulcer duration of \>4 weeks and \<52 weeks\
No active infection97Zelen et al. \[[@CR29]\]Nonblinded RCT in USA; 2016Patients with DFUsEpiFix + SOC vs. SOCUlcer size ≥1 and \<25 cm^2^\
Ulcer duration ≥4 weeks\
No clinical signs of infection67Zelen et al. \[[@CR25]\]Multicenter, nonblinded RCT in Virginia (USA);; 2015Patients with DFUsEpiFix + SOC vs. SOCUlcer size ≥1 and \<25 cm^2^\
Ulcer duration ≥4 weeks\
No clinical signs of infection40DiDomenico\
et al. \[[@CR26]\]Multicenter RCT in USA; 201623 March 2015 to 23 March 2016; patients with DFUsdHACM + SOC vs. SOCUlcer size \>1 cm^2^\
Ulcer duration ≥4 weeks\
No signs of infections40Snyder et al. \[[@CR28]\]Multicenter, nonblinded RCT in USA; 2016Patients with DFUsDAMA + SOC vs. SOCUlcer  size \>1 and \<25 cm^2^\
Ulcer duration ≥1 month\
No clinical sign of infection or osteomyelitis21 (PP)*AHAM* Acellular human amniotic membrane, *DAMA* Dehydrated amniotic membrane allograft, *DFUs* diabetic foot ulcers,*dHACM* dehydrated human amnion/chorion membrane, *IW* infected wounds, *PP* per protocol*RCT* randomized control trial, SOC standard of care/standard therapy Table 2Characteristics of the commercial amniotic membrane products used in the seven studies included in the meta-analysisAmniotic membrane productsManufacturerComponentsProcessing methodApplicationAmnioexcel \[[@CR28]\]Derma SciencesAmnionDehydrationPatchEpifix \[[@CR24], [@CR25], [@CR29]\]MiMedxAmnion and chorionDehydrationPatchGrafix \[[@CR30]\]Osiris TherapeuticsAmnion and chorionCryopreservationPlastic applicatorAmnioBand \[[@CR26]\]Musculoskeletal Transplant FoundationAmnion and chorionDehydrationGraft applicationLife Patch \[[@CR27]\]International Bioimplant Co., Tehran, IranAmnionDecellularizationPatch

Study Characteristics {#Sec8}
---------------------

In all studies, minimum management consisted of standard care of the wound (SOC). In the intervention groups, treatment with amniotic membrane was added to the therapeutic regimen. As result, data comparing amniotic membrane + standard therapy versus standard therapy alone were considered (Table [3](#Tab3){ref-type="table"}). As in the RCT of Snyder et al. \[[@CR28]\], we considered per protocol subjects because eight patients were withdrawn at an early stage (4 in each group).Table 3Illustration of intervention group versus control groupAuthorManagement of Intervention groupManagement of control groupMohajeri-Teherani et al. \[[@CR27]\]Use of bio-implant dressing (acellular human amniotic collagen membrane) weekly + sterile gauze and adhesive tape daily (*n* = 27)Use of sterile gauze and adhesive tape daily (*n* = 30)Zelen et al. \[[@CR24]\]Debridement, Epifix (dehydrated human amniotic membrane allograft), non-adherent dressing, compression dressing and offloading (*n* = 13)Debridement, moist dressing, compression dressing and offloading (*n* = 12)zelen et al. \[[@CR25]\]Epifix, debridement, moist dressing, compressive dressing, ulcer measurement and photography, non-adherent dressing and offloading (*n* = 20)Debridement, collagen alginate and gauze dressing, ulcer measurement, photography and offloading (*n* = 20)Zelen et al. \[[@CR29]\]Epifix, debridement, cleansing with normal sterile saline solution, ulcer measurement and photography, non-adherent dressing, offloading (*n* = 32)Debridement, cleansing with normal saline solution, collagen-alginate and gauze dressing, ulcer measurement and photography, offloading (*n* = 35)DiDomenico et al. \[[@CR26]\]Offloading, appropriate debridement, moist dressing, dHACM (*n* = 20)Offloading, appropriate debridement, moist dressing \[*n* = 20\]Lavery et al. \[[@CR30]\]Standard wound care (debridement, offloading, non-adherent dressing, saline moistened gauze, Grafix (cryopreserved human amniotic membrane) (*n* = 50)Standard wound care (debridement, offloading, non-adherent dressing, saline moistened gauze) (*n* = 47)Snyder et al. \[[@CR28]\]Debridement, moist dressing, offloading, infection surveillance and management, DAMA (PP, *n* = 11)Debridement, moist dressing, offloading, infection surveillance and management (PP, *n* = 10)

Patients Characteristics {#Sec9}
------------------------

The baseline characteristics regarding age, gender, body mass index, percentage glycated hemoglobin, ankle brachial index, ulcer type, ulcer location, ulcer etiology, wound surface area, wound duration, infection and Wagner grade of patients were comparable between the intervention group (HACM + SOC) and control group (SOC). There were no statistically significant differences at baseline between the intervention group and control group in all studies.

Risk of Bias {#Sec10}
------------

Risk of bias assessment for each study is summarized in Table [4](#Tab4){ref-type="table"}. All included studies were of high quality.Table 4Risk of bias of the studiesAuthorEntryJudgmentSupport judgmentZelen et al. \[[@CR24]\]Random sequenceLow riskPatients were randomly assignedAllocation concealmentUnclearNot statedBlinding personnelHigh riskNo blindingBlinding participantHigh riskNo blindingBlinding outcomeUnclearNot statedIncomplete outcomeLow riskAll participants were followed until the endSelective reportingLow riskThe endpoint was expectedZelen et al. \[[@CR25]\]Random sequenceLow riskPatients were randomly assigned and divided into 2 groupsAllocation concealmentLow riskAn envelope was randomly shuffled and labeledBlinding personnelHigh riskPhysicians were aware of treatmentBlinding participantHigh riskNo blinding because of different handling requirementsBlinding outcomeLow riskExperts of wounds were blindedIncomplete outcomeLow riskAll randomized patients were followed until the endSelective reportingLow riskThe endpoint was expectedZelen et al. \[[@CR29]\]Random sequenceLow riskPatients were randomly assignedAllocation concealmentLow riskPlacing each sheet of paper in an envelope and sealing itBlinding personnelHigh riskNo blindingBlinding participantHigh riskNo blindingBlinding outcomeUnclearNot statedIncomplete outcomeLow riskAll randomized patients were followed until the end of studySelective reportingLow riskThe endpoint was expectedLavery et al. \[[@CR30]\]Random sequenceLow riskPatients were randomly assignedAllocation concealmentUnclearNot statedBlinding participantLow riskSingle blinded studyBlinding personnelHigh riskNo blindingBlinding OutcomeLow riskTwo blinded wound care expertsIncomplete outcomeLow riskAll randomized patients were followed until the endSelective reportingLow riskExpected endpointMohajeri-Tehrani et al. \[[@CR27]\]Random sequenceLow riskRandomly assignedAllocation concealmentUnclearNot statedBlinding participantHigh riskPatients were informed about the studyBlinding personnelUnclearNot statedIncomplete outcomeLow riskAll randomized patients were followed until the endBlinding outcomeUnclearNot statedSelective reportingLow riskThe endpoint was expectedSnyder et al. \[[@CR28]\]Random sequenceLow riskPatients were randomly assignedAllocation concealmentUnclearNot statedBlinding participantHigh riskOpen-label studyBlinding personnelHigh riskOpen-label studyIncomplete outcomeLow riskAll PP randomized patients were followed until the endBlinding outcomeUnclearNot statedSelective reportingLow riskExpected endpointDiDomenico et al. \[[@CR26]\]Random sequenceLow riskPatients were randomly assignedAllocation concealmentLow riskPlacing each sheet of paper in envelope and sealing itBlinding personnelLow riskSite investigators were not aware of methods usedBlinding patientsUnclearNot statedBlinding outcomeLow riskIndependent physicians were blindedIncomplete outcomeLow riskAll randomized patients were followed until the endSelective reportingLow riskExpected endpoint

Outcome {#Sec11}
-------

There were far fewer unhealed wounds in patients receiving amniotic membrane + SOC treatment than in those receiving SOC alone. The overall effect in the group assessed at 4 weeks was *Z* = 4.14 (*P* \< 0.0001; OR 0.05; 95% CI 0.01--0.21). The overall effect in the group assessed at 6 weeks was *Z* = 4.28 (*P* \< 0.0001; OR 0.07; 95% CI 0.02--0.23). The overall effect in the group assessed at 12 weeks was *Z* = 4.96 (*P* \< 0.00001; OR 0.10; 95% CI 0.04--0.24.

The heterogeneity in each subgroup was not statistically significant. In the subgroup assessed at 4 weeks, *I* ^2^ = 0% (*P* = 0.32); in the subgroup assessed at 6 weeks, *I* ^2^ = 47% (*P* = 0.11); in the subgroup assessed at 12 weeks, *I* ^2^ = 24% (*P* = 0.27).

In the test for subgroup differences, the heterogeneity was also not statistically significant. For the subgroup differences, *I* ^2^ = 0% (*P* = 0.76)

Discussion {#Sec12}
==========

The results of this systematic review and meta-analysis show that amniotic membrane is beneficial for treating chronic DFUs when it is combined with the SOC. Several earlier studies have already shown the great efficacy of the combined treatment amniotic membrane + SOC in enhancing the healing of complicated wounds. Our results enrich these previous findings.

In all subgroups assessed, the efficacy of treatment with amniotic membrane was remarkable. The overall effect of incomplete wound healing between the intervention group and control group at 4, 6 and 12 weeks was *Z* = 4.14 (*P* \< 0.0001; OR 0.05; 95% CI 0.01--0.21), *Z* = 4.28 (*P* \< 0.0001; OR 0.07; 95% CI 0.02--0.23) and *Z* = 4.96 (*P* \< 0.00001; OR 0.10; 95% CI 0.04--0.24), respectively. In all three subgroups, the odds ratio and their standard deviation were \<1, indicating that the incomplete healing outcomes are less associated with amniotic membrane + SOC. In addition, in all the groups, the *P* value was \<0.05. There is statistically significant difference between the intervention group (HACM + SOC) and the control group (SOC). Those results support previous findings that the amniotic membrane + SOC treatment has a greater efficacy for wound healing than SOC alone. This combined treatment strategy allows wound closure faster than the SOC, which is in turn beneficial for the treatment of DFUs. In fact, the main goal of DFU treatment is to promote rapid and complete healing in order to reduce the risk for infection, amputation and other forms of related complications.

The use of placental membranes for wound healing was first reported towards the middle of the last century \[[@CR32]\]. Initially, the amnion was predominantly viewed as a treatment for burns, and reports on its use in the treatment of chronic ulcers was limited to a few cases and studies \[[@CR33]--[@CR35]\]. However, more recently it has been shown that the human amnion/chorion membrane is beneficial for treating and healing DFUs \[[@CR24]--[@CR30]\].

The intrinsic properties of the amnion explain its efficacy in enhancing the healing of chronic DFUs. HACM has the potential to positively affect four distinct and pivotal physiological processes closely involved in wound healing, namely cell proliferation, inflammation, metalloproteinase activity and recruitment of progenitor cells \[[@CR19]\]. HACM also has the potential to promote revascularization and tissue healing within poorly vascularized, non-healing wounds as it contains angiogenic growth factor that retains biological activity \[[@CR36]\]. The low immunogenicity of HACM also permits its allogeneic use. It acts as a physical barrier against bacterial contamination and also creates the moist environment required for healing. Furthermore, it reduces pain and has anti-inflammatory, anti-fibrotic, and anti-microbial activities that are beneficial to wound healing \[[@CR22], [@CR37]\].

Our assessment of unhealed wounds showed no statistical difference in unhealed wounds at the 4-week and 6-week time points (*Z* = 4.14; *P* \< 0.0001; OR 0.05, 95% CI 0.01--0.21 vs. *Z* = 4.28; *P* \< 0.0001; OR 0.07; 95% CI 0.02--0.23, respectively). There was a statistical difference at 12 weeks (*Z* = 4.96; *P* \< 0.00001; OR 0.10; 95% CI 0.04--0.24. Thus, the sensitivity to the intervention at 4 weeks was almost the same as that at 6 weeks but it was statistically different from that at 12 weeks. Our analysis reveals that when using HACM as adjuvant therapy in patients with DFUs, the optimal times to assess healing should be 4 weeks and 12 weeks. This result correlates positively with previous findings. It should be noted that when SOC alone is used as treatment, a wound that does not decrease in area by ≥40% at 4 weeks has very little chance of healing at 12 weeks \[[@CR14]\]; therefore, other treatments should be considered. Early decrease in size indicates a good prognosis. In fact, 4 weeks of observation is a robust predictor of healing at 12 weeks \[[@CR38]\].

In addition, amniotic membrane products are relatively inexpensive and even more effective \[[@CR29]\]. As such, such products should be useful in low-income countries.

The studies included in the meta-analysis have a number of limitations. Although we observed a great efficacy of amniotic membrane treatment in these studies, it cannot be used alone. The SOC must be accompanied by at least debridement and dressing changes. Secondly, most of our studies assessed the amniotic membrane effect in clinically uninfected wounds, with the only exception being the study of Mohajeri-Tehrani et al. \[[@CR27]\] in which some clinically infected wounds were included. As HACM has antibacterial properties, more RCTs are needed to assess the efficacy of this treatment in clinically infected wounds. It is not always straightforward to rule out infections in initially clinically uninfected wounds of diabetic patients. Finally, the number of studies and the sample sizes were not sufficiently large, which can increase biases.

Conclusions {#Sec13}
===========

This systematic review and meta-analysis included studies conducted in different countries. The final results demonstrate that human amnion/chorion membrane + standard of care heals DFUs significantly faster than SOC alone. Based on the current evidence of this meta-analysis and previous findings, we suggest that when HACM is used to treat patients with DFUs, the optimal times to assess healing should be 4 weeks and 12 weeks. Further, large-sized studies or RCTs are still needed to verify our findings and assess healing in infected DFUs.
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